The invention is directed to natural drug compositions comprising turmeric, boswellia and ginger. Methods for the use of the inventive drug compositions in the treatment of inflammatory disorders and melanoma are within the scope of the invention.

The present invention relates to budesonide, or a salt thereof, or mixtures thereof for ophthalmic use in a method for the curative treatment of an eye disorder or ailment or disease in a subject in need. Further, the present invention relates to a composition comprising a mixture comprising or, alternatively, consisting of: (i) a budesonide, or a salt thereof, or mixtures thereof; (ii) at least one suspending/thickening agent, and optionally one or more physiologically and/or pharmacologically acceptable excipients; said composition being for use in a method for the curative treatment of an inflammation of the and ocular adnexa or inflammation of the eyeball in a subject in need.

The disclosure relates generally to bacterial strains of the genus Anaerostipes, e.g., Anaerostipes rhamnosivorans bacterial strains, and compositions, e.g., pharmaceutical compositions, comprising such bacterial strains. The disclosure further relates to method of using such bacterial strains and compositions for preventing or treating a disorder, e.g., an inflammatory disorder, a gastrointestinal disorder, a metabolic disorder, and/or dysbiosis when administered to a subject in need thereof.

The disclosure relates generally to bacterial strains of the genus Anaerostipes, e.g., Anaerostipes rhamnosivorans bacterial strains, and compositions, e.g., pharmaceutical compositions, comprising such bacterial strains. The disclosure further relates to method of using such bacterial strains and compositions for preventing or treating a disorder, e.g., an inflammatory disorder, a gastrointestinal disorder, a metabolic disorder, and/or dysbiosis when administered to a subject in need thereof.

A composition is based on N-palmitoyl-ethanolamide and Baicalein in the co-micronized form. The includes a mixture of palmitoyl-ethanolamide (PEA) and Baicalein in co-micronized form. The composition is usable for treating benign prostatic hyperplasia.

A composition is based on N-palmitoyl-ethanolamide and Baicalein in the co-micronized form. The includes a mixture of palmitoyl-ethanolamide (PEA) and Baicalein in co-micronized form. The composition is usable for treating benign prostatic hyperplasia.

A suspension includes an ophthalmic active ingredient suspended in a formulation vehicle including a suspending agent and a non-ionic cellulose derivative. The ophthalmic active agent is present as particles having D.sub.v90<5 μm and D.sub.v50<1 μm. The suspension may be administered to a patient for treating an ophthalmic inflammatory condition.

A suspension includes an ophthalmic active ingredient suspended in a formulation vehicle including a suspending agent and a non-ionic cellulose derivative. The ophthalmic active agent is present as particles having D.sub.v90<5 μm and D.sub.v50<1 μm. The suspension may be administered to a patient for treating an ophthalmic inflammatory condition.

Protein-based nanoparticles and methods of forming such protein-based nanoparticles via electrohydrodynamic jetting methods are provided. The nanoparticle may comprise a water-soluble protein having an average molecular weight of ≥ about 8 kDa and < about 700 kDa. In certain variations, the water-soluble protein is cross-linked (e.g., with an optional crosslinking agent) and defines a mesh structure having an average linear mesh size of ≥ about 1 nm to ≤ about 4 nm. Methods of making such nanoparticles may include jetting a liquid comprising the water-soluble protein through a nozzle, followed by exposing the liquid to an electric field sufficient to solidify the liquid and form the protein-based nanoparticles described above.

C

The present invention discloses a method for analysis of drug resistance of tumor cells. The method includes the steps of: (a) providing silicon dioxide nanoparticles, polystyrene-co-polyacrylic acid nanoparticles or metal-organic framework nanoparticles; (b) co-incubating the silicon dioxide nanoparticles, the polystyrene-co-polyacrylic acid nanoparticles or the metal-organic framework nanoparticles with the tumor cells; and (c) detecting endocytosis of the silicon dioxide nanoparticles, the polystyrene-co-polyacrylic acid nanoparticles or the metal-organic framework nanoparticles by the tumor cells. The analysis method of the present invention can analytically identify drug-resistant tumor cells in a clear, intuitive and efficient way. The provided nanoparticles feature simple synthesis processes that take short periods of time, and after they are co-incubated with the tumor cells, a flow cytometer is used for detection. Based on a result of the detection, a degree of drug-resistance of the tumor cells and a proportion of drug-resistant cells therein are determined, making the method simple and efficient.